Citi is out with its report today on Medtronic MDT, lowering its PT to $46 from $40.
In its report, Citi writes, "Our last target price change occurred before the recent market correction which has led to a 15% reduction in the peer group multiple. Hence, our target price drops from $46 to $40. MDT still trades at a sharp discount to its peer group – an 8.5x C2012 P/E vs. 11.3x for large cap med tech – but will likely take a bit longer than we hoped to make up the difference."
Citi maintains Buy on MDT.
Shares of MDT closed Friday at $31.54, up 1.15% from Thursday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in